Navigation Links
Tiny capsules deliver
Date:1/12/2009

A tiny particle syringe composed of polymer layers and nanoparticles may provide drug delivery that targets diseased cells without harming the rest of the body, according to a team of chemical engineers. This delivery system could be robust and flexible enough to deliver a variety of substances.

"People probably fear the effects of some treatments more than they fear the disease they treat," says Huda A. Jerri, graduate student, chemical engineering. "The drugs are poison. Treatment is a matter of dosage so that it kills the cancer and not the patient. Targeted treatment becomes very important."

Newer approaches to drug delivery include particles that find specific cells, latch on and release their drugs. Another approach allows the cells to engulf the particles, taking them into the cell and releasing the drug. However, the requirements for these delivery systems are complicated and challenging to implement.

The Penn State researchers' approach produces a more universal delivery system, a tiny spherical container averaging less than 5 microns or the diameter of the smallest pollen grains.

The spheres are formed around solid microparticles that are either the drug to be delivered or a substance that can be removed later leaving a hollow sphere for liquid drugs. They reported their results online in Soft Matter.

Alternating positive and negative layers of material form the microcapsules. The capsules are created while attached to a flat surface so the section of the sphere touching the surface is not coated, leaving about 5 percent of the surface as an escape area for the drugs. The microcapsule, excluding the exit hole, is then covered in a slippery, non-stick barrier coating.

"These are not the first microcapsules for drug delivery developed, but a previous attempt had surfaces that stuck together and clumped," says Velegol. "We also designed the tiny hole in the sphere for controlled delivery and that is a new development."

Targeted drug delivery systems release their drug from the moment they enter the body. The microsyringes, however, while releasing material continuously, do so only from the tiny hole in their surface and not from the other 95 percent of the sphere's surface. This will concentrate the drug at the target and reduce the amount of toxins circulating in the body.

"These particles are delivery vessels to which you can add whatever you want when you need it," says Jerri. "Drugs can be either solid -- incorporated when the capsules are made -- or liquid -- filled later. Chemicals that target the diseased cells can be attached in a variety of ways."

To serve as viable, flexible drug delivery systems, these microcapsules should be off the shelf and not completely tailor made for each application. The researchers tested the robustness of the microsyringes by dehydrating and then reconstituting them. Their ability to withstand long periods dried out and then successfully rehydrate is important both for shelf life and because that is the way that liquid medications will be inserted in the microcapsules as needed.

To ensure that the spheres refill, the researchers used a solution containing fluorescent dyes. The filling and emptying of the microcapsules are controlled by the acidity of the liquid in which the tiny beads float. Successful rehydration and filling suggest that these microsyringes could be manufactured and stored until needed. They could then be filled with the appropriate drug and have the proper targeting agent attached to treat specific diseases and patients.

"The masking process used to manufacture these microcapsules is relatively inexpensive, current technology and is scalable," says Velegol. "This means they could be mass produced."


'/>"/>

Contact: A'ndrea Elyse Messer
aem1@psu.edu
814-865-9481
Penn State
Source:Eurekalert  

Related medicine news :

1. Mylans Matrix Receives Final FDA Approval for the Generic Version of the Antiretroviral Zerit(R) Capsules
2. Barr Confirms Patent Challenge of Amrix(R) Extended-Release Capsules, 15mg & 30mg
3. Mylan Receives Final FDA Approval for the Generic Version of the Antidepressant Sarafem(R) Pulvules(R) Capsules
4. Watson Launches Omeprazole Delayed-Release Capsules, 40MG
5. Watson Launches Generic MARINOL(R) Capsules
6. Roxane Laboratories, Inc. Announces the Launch of Ramipril Capsules
7. Lupin Launches Ramipril Capsules
8. Mylan Announces Final FDA Approval for Zaleplon Capsules
9. Watson Receives Final Approval of Omeprazole Delayed-Release Capsules
10. Watson Receives FDA Approval of Potassium Chloride Extended-Release Capsules
11. FDA Approves Luvox(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD)
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Tiny capsules deliver
(Date:10/13/2017)... IL (PRWEB) , ... October 13, 2017 , ... ... which established the certification process to promote standards of excellence for the field ... Symposium, scheduled for March 22 – 25, 2018 in Orlando, Florida at the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Many families have ... many long-term care insurance companies have a waiver for care if the client has ... period, when the family pays for care, is often waived, so the benefits from ...
(Date:10/13/2017)... ... 13, 2017 , ... Talented host, actor Rob Lowe, is ... a new episode of "Success Files," which is an award-winning educational program broadcasted ... each subject in-depth with passion and integrity. , Sciatica occurs when the sciatic ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... ... ... Asante, a nationally recognized health system in southern Oregon, ... health joint venture through an agreement, effective October 1, 2017, to create AccentCare ... company with Asante, delivering clinically integrated care, for the past eight years. This ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
(Date:9/22/2017)... ROCKVILLE, Md. , Sept. 22, 2017  As ... by Republican Senators Bill Cassidy (R-LA) and ... Kalorama Information notes that the medical device industry is ... the medical device tax, the 2.3% excise tax on ... Act.  But they also want covered patients, increased visits ...
(Date:9/19/2017)... Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, ... tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , PhD, ...
Breaking Medicine Technology: